Precigen reports durable long-term responses for PAPZIMEOS in RRP
Precigen released new long-term follow-up data for its RRP therapy, PAPZIMEOS, showing 83% of complete responders maintained efficacy for at least 36 months. This result strengthens the therapy's post-approval clinical profile. Durability is now its key commercial differentiator in a market defined by chronic surgical intervention.
Drug Profile
PAPZIMEOS (prademagene zamikeracel) is an autologous TCR T-cell therapy designed to provide a definitive, non-surgical treatment for RRP. The therapy involves extracting a patient's T-cells and genetically modifying them *ex vivo* to express a T-cell receptor that recognizes the E6 and E7 antigens presented by HPV 6 and HPV 11.
Structurally, its primary differentiator is the use of Precigen's non-viral UltraVector® platform for gene delivery, which contrasts with the lentiviral or retroviral vectors common in other cell therapies. After modification, these engineered T-cells are infused back into the patient. They are designed to systemically target and eliminate the HPV-infected cells that cause papilloma growth, addressing the underlying viral reservoir rather than just the symptoms.
Clinical Data
| Endpoint | Result | Comparator | Trial | | :--- | :--- | :--- | :--- | | Durability of Complete Response | 83% (15 of 18) of complete responders maintained response for ≥36 months | Single-arm study | Phase 1/2 (Long-term follow-up) | | Reduction in Surgeries | 89% of patients (16 of 18) had a >50% reduction in surgeries needed post-treatment | Intra-patient control (12 months prior) | Phase 1/2 (Pivotal data) |
Global Regulatory Status
Drug-specific status across all four regulatory bodies BrunoSan tracks. Separate from pipeline volume shown in the infobar.
| Regulatory Body | Status | Notes |
|---|---|---|
| Agency | Status | |
| FDA (US) | ✓ Approved October 9, 2024 for adult patients with Recurrent Respiratory Papillomatosis (RRP). Granted Orphan Drug, Fast Track, and Regenerative Medicine Advanced Therapy (RMAT) designations. | |
| EMA (Europe) | No submission entry detected in BrunoSan DB as of 2026-06-01. | |
| Health Canada | No submission entry detected in BrunoSan DB as of 2026-06-01. | |
| ANVISA (Brazil) | No submission entry detected in BrunoSan DB as of 2026-06-01. |
STATUS
Market Impact
The market for RRP has been structurally defined by a cycle of surgical intervention. The standard of care involves repeated laryngoscopic procedures to debulk papillomas and maintain an open airway, a process that is costly, burdensome for patients, and fails to address the persistent underlying HPV infection. PAPZIMEOS is the first therapy approved to directly treat the cause of the disease. Its primary competitor is not another pharmaceutical, but the entrenched surgical treatment paradigm. This new durability data is a direct challenge to that paradigm, shifting the clinical narrative from managing symptoms to achieving a sustained, long-term, and potentially curative response with a single administration.
The structural forces governing adoption will center on market access and cost-effectiveness. As an autologous cell therapy, PAPZIMEOS carries a high upfront cost. However, the economic calculus for payers must account for the offset costs of a lifetime of recurrent surgeries, anesthesia, and hospital visits. The seven-year orphan drug exclusivity granted by the FDA provides Precigen with a protected runway to establish its commercial footprint. The new durability data provides critical evidence for pharmacoeconomic models and will be a central tool in negotiations with payers to justify the therapy's cost by demonstrating long-term value and reduced downstream healthcare utilization.
Based on BrunoSan pipeline data tracking 14,934 global development events, PAPZIMEOS's trajectory is currently confined to the US market. Our database shows no active submissions with the EMA (2,202 entries tracked), Health Canada (11,361 entries tracked), or ANVISA. While this new durability data solidifies its value proposition for US payers and strengthens its position against the surgical standard of care, the absence of ex-US regulatory engagement is now the primary limiting factor to its global commercial ceiling. The next value inflection point for Precigen is the initiation of a European marketing authorization application.